Adherence to oral anticoagulant therapy in patients with atrial fibrillation: focus on non-vitamin K antagonist oral anticoagulants

Research output: Contribution to journalArticlepeer-review

Standard

Adherence to oral anticoagulant therapy in patients with atrial fibrillation : focus on non-vitamin K antagonist oral anticoagulants. / Raparelli, Valeria; Proietti, Marco; Cangemi, Roberto ; Lip, Gregory; Lane, Deirdre; Stefania, Basili.

In: Thrombosis and Haemostasis, Vol. 2017, No. 2, 2017, p. 209-218.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{9edfff461b804986b51a00ece24712db,
title = "Adherence to oral anticoagulant therapy in patients with atrial fibrillation: focus on non-vitamin K antagonist oral anticoagulants",
abstract = "Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major adverse events and medication adherence is central to achieve good anticoagulation control. Non-vitamin K antagonist oral anticoagulants (NOACs) are as effective and safe as vitamin K antagonist (VKAs) in NVAF patients. Due to the absence of routine anticoagulation monitoringwith NOACs treatment, concerns have been raised about patient{\textquoteright}s adherence to NOACs and reallife data demonstrates variability in adherence and persistence. A multi-level approach, including patients{\textquoteright} preferences, factors determining physicians{\textquoteright} prescribing habits and healthcare system infrastructure and support, is warranted to improve initiation and adherence of anticoagulants.Adherence to NOACs is paramount to achieve a clinical benefit. Implementation of educational programs and easy-to-use tools to identify patients most likely to be non-adherent to NOACs, are central issues in improving the quality of NVAF anticoagulation management. ",
keywords = "atrial fibrillation, oral anticoagulation, non-vitamin K antagonist oral anticoagulants, adherence, persistence",
author = "Valeria Raparelli and Marco Proietti and Roberto Cangemi and Gregory Lip and Deirdre Lane and Basili Stefania",
year = "2017",
doi = "10.1160/TH16-10-0757",
language = "English",
volume = "2017",
pages = "209--218",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer",
number = "2",

}

RIS

TY - JOUR

T1 - Adherence to oral anticoagulant therapy in patients with atrial fibrillation

T2 - focus on non-vitamin K antagonist oral anticoagulants

AU - Raparelli, Valeria

AU - Proietti, Marco

AU - Cangemi, Roberto

AU - Lip, Gregory

AU - Lane, Deirdre

AU - Stefania, Basili

PY - 2017

Y1 - 2017

N2 - Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major adverse events and medication adherence is central to achieve good anticoagulation control. Non-vitamin K antagonist oral anticoagulants (NOACs) are as effective and safe as vitamin K antagonist (VKAs) in NVAF patients. Due to the absence of routine anticoagulation monitoringwith NOACs treatment, concerns have been raised about patient’s adherence to NOACs and reallife data demonstrates variability in adherence and persistence. A multi-level approach, including patients’ preferences, factors determining physicians’ prescribing habits and healthcare system infrastructure and support, is warranted to improve initiation and adherence of anticoagulants.Adherence to NOACs is paramount to achieve a clinical benefit. Implementation of educational programs and easy-to-use tools to identify patients most likely to be non-adherent to NOACs, are central issues in improving the quality of NVAF anticoagulation management.

AB - Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major adverse events and medication adherence is central to achieve good anticoagulation control. Non-vitamin K antagonist oral anticoagulants (NOACs) are as effective and safe as vitamin K antagonist (VKAs) in NVAF patients. Due to the absence of routine anticoagulation monitoringwith NOACs treatment, concerns have been raised about patient’s adherence to NOACs and reallife data demonstrates variability in adherence and persistence. A multi-level approach, including patients’ preferences, factors determining physicians’ prescribing habits and healthcare system infrastructure and support, is warranted to improve initiation and adherence of anticoagulants.Adherence to NOACs is paramount to achieve a clinical benefit. Implementation of educational programs and easy-to-use tools to identify patients most likely to be non-adherent to NOACs, are central issues in improving the quality of NVAF anticoagulation management.

KW - atrial fibrillation

KW - oral anticoagulation

KW - non-vitamin K antagonist oral anticoagulants

KW - adherence

KW - persistence

U2 - 10.1160/TH16-10-0757

DO - 10.1160/TH16-10-0757

M3 - Article

VL - 2017

SP - 209

EP - 218

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 2

ER -